- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00817284
Bevacizumab and Irinotecan or Bevacizumab and Temozolomide With Concomitant Radiotherapy for Primary Glioblastoma Multiforme (GBM)
A Randomized Phase II Trial With Bevacizumab, Irinotecan and Cerebral Radiotherapy Versus Bevacizumab, Temozolomide and Cerebral Radiotherapy as First Line Treatment for Patients With Glioblastoma Multiforme
Significant activity (radiographic response rates of approximately 60%) has recently been demonstrated in phase II studies in patients with relapsed GBM from the combined use of Irinotecan (CPT-11) and bevacizumab. The 6-month progression-free survival rate is 30% and median survival duration is 9 months. The current first line therapy of GBM patients following initial surgical resection/debulking is the concomitant use of cerebral radiotherapy and the orally available alkylating agent temozolomide, followed by temozolomide for 6 months post-radiotherapy.
Considering the significant activity of the combination of Bevacizumab + irinotecan in patients with recurrent GBM, and considering the activity of temozolomide in GBM, it is proposed that the combination of Bevacizumab + Temozolomide may also be an active regimen. Bevacizumab + Temozolomide display non-overlapping toxicity clinically and thus their combined use without significant dose-reductions seems rational.
The toxicity from the combined use of the two drugs prior to radiotherapy, as well as the toxicity when administered together with radiotherapy, is evaluated.
This study will try to identity whether Bevacizumab and Irinitecan or Bevacizumab and Temozolomide should be the experimental arm in future phase III comparison with standard care with concomitant Temozolomide and radiotherapy.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Copenhagen, Denmark
- Rigshospitalet
-
Odense, Denmark
- Odense Hospital
-
Århus, Denmark
- Århus Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Signed informed consent
- Histological verified primary glioblastoma multiforme
- No prior therapy for GBM, except for primary surgical resection or biopsy
- PS 0-2
- Age > 18
- Expected survival > 3 months
Adequate liver, renal and bone-marrow function, determined as:
- Thrombocytes > 100 x 109/liter
- Hemoglobin >6.2 mmol/liter
- Leukocytes > 3 x 109/liter
- Neutrophil granulocytes > 1.5 x 109/liter
- ASAT and/or ALAT < 3 x upper normal limit
- Bilirubin < 1.5 x upper normal limit
- Serum-creatinin < upper normal limit or glomerular filtration rate >60 ml/min (corrected for age) determined by measurement of clearance of Cr-EDTA
- APTT < upper normal limit
- INR < upper normal limit
- Fertile women of childbearing age must use proper anti-conception (oral contraceptives, IUD and/or condom). Fertile men must use condom
- No sign of cerebral bleeding on cerebral MR-scanning at baseline.
Exclusion criteria:
- Previous therapy of GBM, including radiotherapy and the use of biological " targeted" drug, e.g. drugs targeted against the VEGF- or EGFR pathway
- Concurrent use of medication that can affect the interpretation of the results from the study, e.g. use of immunosuppressive drugs, except corticosteroids
- Conditions (medical, social or physical) that may compromise proper information and/or follow-up
- Other concurrent or previous cancer within 5 years, except adequately treated basal or planocellular skin cancer, or cervical carcinoma in situ
- Significant heart disease (according to the New York Heart Association class II or more severe), clinically significant arrhythmia or unstable angina pectoris/acute myocardial infarction within last 6 months
- Clinical significant peripheral arterial disease
- Known or suspected disorders of coagulation or concurrent therapy with ASA, NSAID or clopidogrel
- Major surgery, open biopsy or greater trauma, or expectations thereof, within 28 days prior to start of therapy
- Minor surgery or needle biopsy, or expectations thereof, within 7 days prior to start of therapy
- Known or suspected abdominal fistulas, gastrointestinal perforations or intra-abdominal abscesses within 6 months prior to start of therapy
- Chronic inflammatory intestinal disease and/or intestinal obstruction
- Known or active HIV or Hepatitis B/C infection
- Concurrent ongoing significant infection or diabetes mellitus not adequately controlled medically
- Clinically significant non-healing ulcers
- Active ventricular or duodenal ulcers within 6 months prior to start of therapy
- Recent bone-fracture (<3 months)
- Pregnancy or lactation
- Need for systemic anticoagulant therapy at time of start of therapy
- Blood pressure > 150/100 mmHg (patients are allowed to receive proper antihypertensive medication)
- Proteinuria ≥ 1 gram/day
- Known allergy toward irinotecan (or related substance) or vehicle
- Known allergy toward temozolomide (or related substance) or vehicle
- Known allergy toward bevacizumab (or related substance) or vehicle
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: arm I
Bevacizumab + Irinotecan and concomitant radiotherapy
|
Radiotherapy is delivered during 3rd and 4th cycle of chemotherapy and consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday to Friday) over a period of six weeks for a total dose of 60 Gy. |
Experimental: Arm II
Bevacizumab and Temozolomide and concomitant radiotherapy
|
Bevacizumab 10 mg/kg is administered on days 1 and 15. Temozolomide dosing before start concomitant chemoradiotherapy: 150 mg/m2/day on days 1-5 during the first 28 days treatment cycle, then 200 mg/m2/day on the subsequent cycles until radiotherapy. Temozolomide administered concomitantly with the radiotherapy: Temozolomide 75 mg/m2/day for 7 days per week is administered on each day of radiotherapy. After completed chemoradiotherapy, temozolomide is dosed and administered as it was prior to start chemoradiotherapy, i.e. temozolomide 200 mg/m2/day on days 1-5 out of a 28 days schedule, taking into consideration any previous dose-reductions already made. Radiotherapy is delivered during 3rd and 4th cycle of chemotherapy and consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday to Friday) over a period of six weeks for a total dose of 60 Gy. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Objective response rate according to McDonald criteria
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression-free survival
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Astrocytoma
- Glioma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioblastoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Topoisomerase Inhibitors
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Topoisomerase I Inhibitors
- Temozolomide
- Bevacizumab
- Irinotecan
Other Study ID Numbers
- BIBT-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioblastoma Multiforme
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States, Belgium, Switzerland, Germany, Netherlands
-
Milton S. Hershey Medical CenterRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)RecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
Leland MethenyNational Cancer Institute (NCI)RecruitingGlioblastoma Multiforme | Supratentorial Gliosarcoma | Glioblastoma Multiforme, Adult | Supratentorial GlioblastomaUnited States
-
University of UtahWithdrawnGlioblastoma Multiforme (GBM)United States
-
Sunnybrook Health Sciences CentreRecruitingGlioblastoma Multiforme, AdultCanada
-
Hebei Senlang Biotechnology Inc., Ltd.RecruitingGlioblastoma Multiforme, AdultChina
-
Polaris GroupRecruitingGlioblastoma Multiforme (GBM)Taiwan
-
University of IowaEisai Inc.TerminatedPrimary Glioblastoma MultiformeUnited States
Clinical Trials on bevacizumab and Irinotecan and radiotherapy
-
Ruijin HospitalRecruitingRecurrent GlioblastomaChina
-
GERCOR - Multidisciplinary Oncology Cooperative...Hoffmann-La RocheActive, not recruitingColorectal Cancer MetastaticIreland, France, Israel
-
Johns Hopkins All Children's HospitalThe V Foundation; Brain Tumor AllianceCompletedCentral Nervous System TumorsUnited States
-
Northwestern UniversityNational Cancer Institute (NCI); Ipsen BiopharmaceuticalsCompletedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Refractory Fallopian Tube... and other conditionsUnited States
-
Cancer Institute and Hospital, Chinese Academy...RecruitingMetastatic Colorectal CancerChina
-
Duke UniversityNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Medical University InnsbruckRoche, AustriaUnknownRecurrent Malignant GliomaAustria
-
Cancer Institute and Hospital, Chinese Academy...UnknownColorectal Cancer | Metastatic Cancer | Colorectal AdenocarcinomaChina
-
Genentech, Inc.Completed
-
Taiho Pharmaceutical Co., Ltd.Completed